U-Neuron Biomedical (ROCO:6973) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is U-Neuron Biomedical Debt-to-Equity?

U-Neuron Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$4.77 Mil. U-Neuron Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$4.90 Mil. U-Neuron Biomedical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$491.97 Mil. U-Neuron Biomedical's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for U-Neuron Biomedical's Debt-to-Equity or its related term are showing as below:

ROCO:6973' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 0.03
Current: 0.02

During the past 4 years, the highest Debt-to-Equity Ratio of U-Neuron Biomedical was 0.03. The lowest was 0.02. And the median was 0.02.

ROCO:6973's Debt-to-Equity is ranked better than
87.83% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6973: 0.02

U-Neuron Biomedical Debt-to-Equity Historical Data

The historical data trend for U-Neuron Biomedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U-Neuron Biomedical Debt-to-Equity Chart

U-Neuron Biomedical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.03

0.02

U-Neuron Biomedical Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	-	N/A	0.03	-	0.02

Competitive Comparison of U-Neuron Biomedical's Debt-to-Equity

For the Biotechnology subindustry, U-Neuron Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U-Neuron Biomedical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's Debt-to-Equity falls into.

U-Neuron Biomedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

U-Neuron Biomedical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.767	+	4.896)	/	491.967
	=	0.02

U-Neuron Biomedical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.767	+	4.896)	/	491.967
	=	0.02

U-Neuron Biomedical (ROCO:6973) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

U-Neuron Biomedical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of U-Neuron Biomedical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

U-Neuron Biomedical (ROCO:6973) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » U-Neuron Biomedical Inc (ROCO:6973) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

https://en.u-neuron.com

U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.

U-Neuron Biomedical (ROCO:6973) Headlines

No Headlines